Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for P3 Health Partners (PIIIW) over the last 5 years, with Q3 2025 value amounting to $14.7 million.

  • P3 Health Partners' Cash from Financing Activities rose 68994.37% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.7 million, marking a year-over-year increase of 4585.14%. This contributed to the annual value of $98.8 million for FY2024, which is 155.58% down from last year.
  • Latest data reveals that P3 Health Partners reported Cash from Financing Activities of $14.7 million as of Q3 2025, which was up 68994.37% from $14.6 million recorded in Q2 2025.
  • P3 Health Partners' 5-year Cash from Financing Activities high stood at $87.2 million for Q2 2023, and its period low was -$2.5 million during Q3 2024.
  • In the last 5 years, P3 Health Partners' Cash from Financing Activities had a median value of $12.3 million in 2021 and averaged $15.5 million.
  • In the last 5 years, P3 Health Partners' Cash from Financing Activities plummeted by 533106.55% in 2022 and then skyrocketed by 713438.26% in 2023.
  • Quarter analysis of 5 years shows P3 Health Partners' Cash from Financing Activities stood at $12.3 million in 2021, then increased by 21.97% to $15.0 million in 2022, then crashed by 105.6% to -$840000.0 in 2023, then skyrocketed by 4113.93% to $33.7 million in 2024, then plummeted by 56.5% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $14.6 million for Q2 2025, and $30.7 million during Q1 2025.